Galapagos NV ADR (GLPG) Stock Price, Quote & News

Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic...

Industry: Biotechnology

Sector: Healthcare

Phone: 32 1 534 29 00

Fax: 32 1 534 29 01

Website: www.glpg.com

Address:

Generaal De Wittelaan L11 A3, Mechelen, Belgium

BillionerOfKing Feb. 28 at 4:38 AM

$GLPG Current Stock Price: $33.70 Contracts to trade: $32.5 GLPG Apr 17 2026 Call Entry: $1.80 Exit: $2.28 ROI: 26% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

erevnon Feb. 25 at 4:04 PM

RBC Capital maintains Galapagos $GLPG at Sector Perform and raises the price target from $32 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StocktwitsEarnings Feb. 23 at 10:25 PM

$GLPG Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $2.44 up 542.11% YoY • Reported revenue of $900.77M up 1093.16% YoY • Galapagos expects to be cash flow neutral to positive by the end of 2026, anticipating 2.78B to 2.85B in cash and financial investments at year-end. Restructuring cash costs are projected between 125M and 175M for 2026.

0 · Reply

OfficialStocktwitsUser Feb. 21 at 4:29 PM

$GLPG RSI: 48.97, MACD: 0.1751 Vol: 0.42, MA20: 34.07, MA50: 33.28 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BillionerOfKing Feb. 5 at 2:25 PM

$GLPG Current Stock Price: $34.62 Contracts to trade: $35.0 GLPG Feb 20 2026 Call Entry: $1.35 Exit: $1.86 ROI: 37% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

MandelbrotMarkets Feb. 4 at 9:55 AM

$GLPG biotech, European R&D

0 · Reply

hegdaom Jan. 27 at 12:18 PM

$CAPR $AUPH $GLPG $TARS

0 · Reply

potrero Jan. 27 at 11:18 AM

$CAPR Tang has a history of ruthlessness with zombie biotechs, as well as a history of validating successful growth stories ($AUPH, $GLPG, $TARS). CAPR is the latter, not the former. Given where Tang accumulated shares in each of the 3 other examples, it's a bullish indication for CAPR.

0 · Reply

mikesterz7 Jan. 6 at 12:03 AM

$GLPG The company had announced its intent to wind down the activities after a strategic review and sale process in October.

0 · Reply

StocktwitsNews Jan. 5 at 9:50 PM

Galapagos Stock Rises After Hours On Starting To Wind Down Cell Therapy Activities, Workforce Reduction $GLPG https://stocktwits.com/news/equity/markets/glpg-stock-rises-after-hours-on-starting-to-wind-down-cell-therapy-activities/cmxMCiBR4RL

0 · Reply

Galapagos Receives Transparency Notifications from Bank of America

2026-03-06T21:10:00.000Z - 8 days ago

Galapagos NV: Galapagos Creates New Subscription Right Plan

Fri, 06 Mar 2026 16:01:00 -0500 - 8 days ago

Galapagos Creates New Subscription Right Plan

2026-03-05T21:10:00.000Z - 9 days ago

Galapagos NV: Galapagos Appoints Tania Philipp as Chief Human Resources Officer

Thu, 05 Mar 2026 16:01:00 -0500 - 9 days ago

Galapagos Appoints Tania Philipp as Chief Human Resources Officer

Wed, 04 Mar 2026 16:01:00 -0500 - 10 days ago

Galapagos Receives Transparency Notifications from Bank of America

2026-03-03T01:00:26.000Z - 12 days ago

Galapagos NV at TD Cowen Healthcare Conference Transcript

2026-02-25T16:33:15.000Z - 17 days ago

GLPG: RBC Capital Raises Price Target, Reaffirms Sector Perform | GLPG Stock News

2026-02-24T19:01:40.000Z - 18 days ago

Galapagos NV (GLPG) Full Year 2025 Earnings Call Highlights: Strategic Shifts and Financial ...

2026-02-24T18:00:25.000Z - 18 days ago

Full Year 2025 Galapagos NV Earnings Call Transcript

2026-02-23T21:52:27.000Z - 19 days ago

Earnings Breakdown: Galapagos Q4

2026-02-23T21:10:00.000Z - 19 days ago

Galapagos NV: Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Mon, 23 Feb 2026 16:01:00 -0500 - 19 days ago

Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

2026-02-23T12:22:21.000Z - 19 days ago

Galapagos NV (XAMS:GLPG) Q4 2025: Everything You Need to Know Ahead of Earnings

2026-02-20T16:00:56.000Z - 22 days ago

A Peek at Galapagos's Future Earnings

2026-02-19T21:10:00.000Z - 23 days ago

Galapagos NV: Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors

Mon, 16 Feb 2026 16:01:00 -0500 - 26 days ago

Galapagos Receives Transparency Notification from Bank of America

2026-02-10T21:10:00.000Z - 4 weeks ago

Galapagos NV: Galapagos Receives Transparency Notifications from Bank of America

2026-01-05T22:00:46.000Z - 2 months ago

Galapagos (GLPG) to Cease Cell Therapy Operations

2026-01-05T21:11:00.000Z - 2 months ago

Galapagos NV: Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities

Mon, 05 Jan 2026 16:01:00 -0500 - 2 months ago

Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities

2025-12-19T04:56:34.000Z - 3 months ago

Galapagos (GLPG) Achieves Key Milestone in Dermatomyositis Study

2025-12-18T21:10:00.000Z - 3 months ago

Galapagos NV: Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus

2025-12-12T11:43:36.000Z - 3 months ago

GLPG Crosses Above Average Analyst Target

2025-12-08T10:50:27.000Z - 3 months ago

Galapagos (GLPG) Showcases Promising Phase 2 Results for CAR T-Cell Therapy

2025-12-08T06:34:00.000Z - 3 months ago

Galapagos NV: Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025

Mon, 08 Dec 2025 01:30:00 -0500 - 3 months ago

Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025

2025-11-26T06:34:00.000Z - 3 months ago

Galapagos NV: Galapagos Receives Transparency Notifications from Bank of America

Wed, 26 Nov 2025 01:30:00 -0500 - 3 months ago

Galapagos Receives Transparency Notifications from Bank of America

2025-11-07T19:48:54.000Z - 4 months ago

RBC Capital Raises Price Target for GLPG to $32. ...

2025-11-06T19:06:53.000Z - 4 months ago

Galapagos NV (GLPG) Q3 2025 Earnings Call Highlights: Navigating Strategic Shifts Amidst ...

2025-11-06T18:20:50.000Z - 4 months ago

Q3 2025 Galapagos NV Earnings Call Transcript

Mon, 03 Nov 2025 16:01:00 -0500 - 4 months ago

Galapagos to Present New Data from Cell Therapy Program at ASH 2025

2025-10-29T11:39:44.000Z - 4 months ago

GLPG Crosses Above Average Analyst Target

Thu, 23 Oct 2025 16:01:00 -0400 - 5 months ago

Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors

2025-10-22T15:35:31.000Z - 5 months ago

RBC Capital Raises Price Target on Galapagos (GLPG) to $28.00 | GLPG Stock News

2025-10-21T22:30:41.000Z - 5 months ago

Galapagos (GLPG) Stock Upgraded by Leerink Partners | GLPG Stock News

2025-10-21T21:30:04.000Z - 5 months ago

Galapagos (GLPG) Stock Outlook Brightens with Analyst Upgrade

2025-10-21T13:05:02.000Z - 5 months ago

Galapagos (GLPG) to Discontinue Cell Therapy Unit, Shares Fall

2025-10-21T11:25:56.000Z - 5 months ago

GILD: Galapagos Plans to Wind Down Cell Therapy Operations

Tue, 21 Oct 2025 03:34:50 -0400 - 5 months ago

Biotech firm Galapagos to wind down cell therapy business

Tue, 21 Oct 2025 01:30:00 -0400 - 5 months ago

Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation

2025-10-21T05:30:00.000Z - 5 months ago

Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation

Thu, 16 Oct 2025 16:01:00 -0400 - 5 months ago

Galapagos Announces Appointment of Fred Blakeslee as General Counsel

Oct 1, 2025, 4:12 PM EDT - 5 months ago

Biotechnology firm Galapagos receives offers for cell-therapy business

GLPG

Oct 1, 2025, 4:01 PM EDT - 5 months ago

Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business

GLPG

$Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma$

Aug 6, 2025, 1:30 AM EDT - 7 months ago

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

GLPG

Jul 23, 2025, 4:03 PM EDT - 8 months ago

Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

Jul 23, 2025, 4:02 PM EDT - 8 months ago

Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors

Jul 23, 2025, 4:01 PM EDT - 8 months ago

Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update

Jun 23, 2025, 1:30 AM EDT - 9 months ago

Galapagos Appoints Aaron Cox as Chief Financial Officer

$Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101$

Jun 18, 2025, 4:01 PM EDT - 9 months ago

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Jun 12, 2025, 4:01 PM EDT - 9 months ago

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

May 13, 2025, 1:36 AM EDT - 10 months ago

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

Apr 23, 2025, 4:01 PM EDT - 11 months ago

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

Apr 15, 2025, 1:30 AM EDT - 11 months ago

Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

Feb 24, 2025, 4:01 PM EST - 1 year ago

Galapagos to Present at Upcoming Investor Conferences

Feb 17, 2025, 4:01 PM EST - 1 year ago

Galapagos receives transparency notification and 13D filing from Tang Capital

Feb 12, 2025, 4:01 PM EST - 1 year ago

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Jan 21, 2025, 12:08 PM EST - 1 year ago

Galapagos To Spin Off Innovative Medicines Business

Jan 8, 2025, 1:30 AM EST - 1 year ago

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Jan 7, 2025, 4:01 PM EST - 1 year ago

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

$Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma$

Dec 7, 2024, 12:30 PM EST - 1 year ago

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Nov 5, 2024, 4:01 PM EST - 1 year ago

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Oct 30, 2024, 4:01 PM EDT - 1 year ago

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 7, 2024, 1:00 AM EDT - 1 year ago

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Oct 1, 2024, 6:00 AM EDT - 1 year ago

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area

Sep 30, 2024, 4:01 PM EDT - 1 year ago

Galapagos receives transparency notification from EcoR1 Capital

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Galapagos receives transparency notification from FMR LLC

$Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma$

Aug 23, 2024, 1:00 AM EDT - 1 year ago

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Aug 1, 2024, 4:01 PM EDT - 1 year ago

BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Galapagos reports half-year 2024 financial results and provides second quarter business update

Jun 14, 2024, 4:01 PM EDT - 1 year ago

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

May 30, 2024, 4:01 PM EDT - 1 year ago

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

May 30, 2024, 4:01 PM EDT - 1 year ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

May 16, 2024, 4:01 PM EDT - 1 year ago

Galapagos creates new subscription right plans

May 15, 2024, 4:01 PM EDT - 1 year ago

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.

May 2, 2024, 4:01 PM EDT - 2 years ago

Galapagos reports first quarter 2024 financial results

Apr 30, 2024, 4:01 PM EDT - 2 years ago

Galapagos' shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

Apr 4, 2024, 4:01 PM EDT - 2 years ago

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Mar 28, 2024, 4:01 PM EDT - 2 years ago

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings

BillionerOfKing Feb. 28 at 4:38 AM

0 · Reply

erevnon Feb. 25 at 4:04 PM

RBC Capital maintains Galapagos $GLPG at Sector Perform and raises the price target from $32 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StocktwitsEarnings Feb. 23 at 10:25 PM

0 · Reply

OfficialStocktwitsUser Feb. 21 at 4:29 PM

0 · Reply

BillionerOfKing Feb. 5 at 2:25 PM

0 · Reply

MandelbrotMarkets Feb. 4 at 9:55 AM

$GLPG biotech, European R&D

0 · Reply

hegdaom Jan. 27 at 12:18 PM

$CAPR $AUPH $GLPG $TARS

0 · Reply

potrero Jan. 27 at 11:18 AM

0 · Reply

mikesterz7 Jan. 6 at 12:03 AM

$GLPG The company had announced its intent to wind down the activities after a strategic review and sale process in October.

0 · Reply

StocktwitsNews Jan. 5 at 9:50 PM

0 · Reply

LehmanLegacy Dec. 25 at 10:20 AM

$GLPG Capital discipline has become the critical gating factor, since capital markets reward discipline over expansion for its own sake. Delivery cadence is becoming the real competitive edge.

0 · Reply

AStrokeOfLuck Dec. 19 at 1:30 AM

$GLPG

0 · Reply

Doozio Dec. 13 at 3:24 PM

$GLPG so much tightness bahhhhtom of da base. They just said no FOLD wen yo sitting on the NUTX. If only they wud give YO a 🐑 tell 🪧 to SPOT them bums sitting at the table 🐒🍌🧠⏰♾️

0 · Reply

BillionerOfKing Dec. 12 at 10:05 PM

$GLPG Current Stock Price: $31.74 Contracts to trade: $30 GLPG Dec 19 2025 Call Entry: $1.71 Exit: $2.73 ROI: 60% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

dgbio Nov. 19 at 4:53 PM

$GLPG So, Gilead is running the show and they don't want cash, they want deals and they don't want competing programs like cell therapy. If they see Galapagos going above its cash value, it's positive but Gosebruch and his board should really show us soon that they can make good deals. https://www.fiercebiotech.com/biotech/gilead-wants-us-rebuild-why-galapagos-cant-go-extinct-despite-turbulent-year

0 · Reply

AlxNT Nov. 15 at 2:53 AM

0 · Reply

AlxNT Nov. 15 at 2:52 AM

$GLPG Very interesting turnaround/asset play!

0 · Reply

US_Bull Nov. 10 at 1:10 PM

$GLPG Exactly they effing around are they shutting down their cell therapy business or not. They are horrible at conveying a clear unequivocal message would you got to a conference a month out if you are shutting down your cell therapy business.

0 · Reply

JarvisFlow Nov. 7 at 7:04 PM

RBC Capital has adjusted their stance on Galapagos ( $GLPG ), setting the rating to Sector Perform with a target price of 28 → 32.

0 · Reply

GregLippmann Nov. 6 at 6:50 PM

Any comparison between these two? Thanks. $SRPT $GLPG

0 · Reply

dgbio Nov. 6 at 1:53 AM

$GLPG The management should show us altetnatives, get some deals done and only then suggest shutting down cell therapy. Sitting on a pile of cash gives us nothing. At the very least they should pay money saved by shutting cell therapy as a special dividend.

0 · Reply

dgbio Nov. 6 at 1:42 AM

$GLPG Showcasing cell therapy at ASH while shutting it down looks bizarre. https://www.glpg.com/press-releases/galapagos-to-present-new-data-from-cell-therapy-program-at-ash-2025/

0 · Reply

Market Cap	2.09B
Revenue (ttm)	1.26B
Net Income (ttm)	362.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	28.85%
Debt to Equity Ratio	0.00

Volume	177,000
Avg Vol	117,300
Day's Range	N/A - N/A
Shares Out	65.90M
Stochastic %K	3%
Beta	0.26
Analysts	Hold
Price Target	$33.88